TwitterFacebookLinkedIn

A compilation of articles, news, study results and other updates in the field of gynecologic oncology.

Entries with titles highlighted in red may be of particular interest to survivors, caregivers or the general public.

PARP Inhibitor Becomes Standard of Care for Advanced Ovarian Cancer Subset
February 7, 2020: Oncology Nursing News – Frontline niraparib (Zejula) is the new standard of care for patients with newly diagnosed, platinum-sensitive advanced ovarian cancer, after the positive results from the phase III PRIMA trial, explained Antonio González-Martín, MD, lead author in the study. Read more.

World Health Organization Outlines Plan to Eliminate Cervical Cancer in Low to Middle Income Countries
February 5, 2020: Cure – The World Health Organization (WHO) has announced its plans for eliminating cervical cancer as a public health problem among low-income to middle-income countries by fully vaccinating 90% of girls by 15 years old, screen 70% of women between the ages of 35 and 45 and provide 90% of patients with disease receiving care. The organization believes not only will this eliminate cervical cancer in these regions within this century, but also prevent millions of deaths, according to two modeling analyses published in The Lancet. Read more.

MEK/PI3K Inhibitor Combo Generates Activity in RAS/BRAF-Mutant Ovarian Cancer
February 4, 2020: Targeted Oncology – Continuous dosing of the MEK inhibitor binimetinib (Mektovi) plus buparlisib (BKM120), a PI3K inhibitor, demonstrated promising activity as treatment of patients with ovarian cancer harboring either a RAS or BRAF mutation, according to results from a phase Ib clinical trial (NCT01363232). Read more.

ASCO Guideline: Germline Testing Recommended for All Women Diagnosed With Epithelial Ovarian Cancer
February 4, 2020: Cancer Therapy Advisor – A retrospective study showed improved survival among patients with ovarian cancer treated with beta-
All women with a diagnosis of epithelial ovarian cancer should be offered testing for specific germline mutations, according to a new recommendation from ASCO. Read more.

Cervical cancer elimination ‘could be achieved’ by 2120
February 3, 2020: Healio – High HPV vaccination coverage for girls and scaled-up screening and treatment may lead to the elimination of cervical cancer in most lower-middle-income countries over the next 100 years, according to results of two modeling studies published in The Lancet. Read more.

Women’s wellness: researchers look at post menopause as key factor in endometrial cancer
February 3, 2020: Medical Xpress – Endometrial cancer is the most common gynecological malignancy in the U.S. and the fourth most common cancer among women. In addition, endometrial cancer incidence rates are on the rise in the western world, suggesting that alterations in environmental factors such as diet, lifestyle, and the vaginal microbiome may be important drivers in its cause. Read more.

Ipilimumab Shows Tolerability and Signals Efficacy in Advanced Cervical Cancer
January 28, 2020: Targeted Oncology – The phase I study of sequential ipilimumab (Yervoy) after chemoradiotherapy as a curative-intent treatment of patients with node-positive cervical cancer included 34 female patients with stage Ib2 to VI cervical cancer with positive pelvic lymph nodes, para-aortic lymph nodes, or both. Read more.

Use of intrauterine devices may decrease risk for ovarian cancer
January 21, 2020: Healio – Previous studies have linked the use of intrauterine devices (IUDs) to reduced risk for cervical and uterine cancer. Based on these findings, Saketh R. Guntupalli, MD, associate professor and director of the division of gynecologic oncology at University of Colorado School of Medicine, and colleagues examined the possible correlation between IUD use and risk for ovarian cancer. Read more.

Is it still reasonable to offer MIS hysterectomy? No.
January 20, 2020: Contemporary OB/GYN – Dr. Amanda Nickles Fader discusses the con side of the MIS argument from the LACC trial controversy. Read more.

Is it still reasonable to offer MIS hysterectomy? Yes.
January 20, 2020: Contemporary OB/GYN – Dr. Wendell Nauman discusses the pro side of the MIS argument from the LACC trial controversy. Read more.

While survival rates soar for other cancers, funding gaps limit progress on cervical and uterine cancer
January 10, 2020: The Verge – There are limited treatment advances for aggressive forms of these diseases. Read more.

Keytruda Approved for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer
January 9, 2020: Cancer Therapy Advisor – The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. Read more.